274 related articles for article (PubMed ID: 32188393)
1. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Zhang X; Zhong S
Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
[TBL] [Abstract][Full Text] [Related]
2. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors.
Najafov A; Shpiro N; Alessi DR
Biochem J; 2012 Dec; 448(2):285-95. PubMed ID: 23030823
[TBL] [Abstract][Full Text] [Related]
3. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
4. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
Najafov A; Sommer EM; Axten JM; Deyoung MP; Alessi DR
Biochem J; 2011 Jan; 433(2):357-69. PubMed ID: 21087210
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
6. Iridoids from Valeriana jatamansi induce autophagy-associated cell death via the PDK1/Akt/mTOR pathway in HCT116 human colorectal carcinoma cells.
Tan YZ; Peng C; Hu CJ; Li HX; Li WB; He JL; Li YZ; Zhang H; Zhang RQ; Wang LX; Cao ZX
Bioorg Chem; 2019 Jun; 87():136-141. PubMed ID: 30884307
[TBL] [Abstract][Full Text] [Related]
7. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
8. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
Yang C; Huang X; Liu H; Xiao F; Wei J; You L; Qian W
Oncotarget; 2017 Jun; 8(24):39185-39197. PubMed ID: 28402933
[TBL] [Abstract][Full Text] [Related]
9. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effects of metformin in cellular models of pheochromocytoma.
Meireles CG; Lourenço de Lima C; Martins de Paula Oliveira M; Abe da Rocha Miranda R; Romano L; Yo-Stella Brashaw T; Neves da Silva Guerra E; de Assis Rocha Neves F; Chapple JP; Simeoni LA; Lofrano-Porto A
Mol Cell Endocrinol; 2022 Jan; 539():111484. PubMed ID: 34637881
[TBL] [Abstract][Full Text] [Related]
11. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
12. Curcumol inhibits the malignant progression of prostate cancer and regulates the PDK1/AKT/mTOR pathway by targeting miR‑9.
Sheng W; Xu W; Ding J; Li L; You X; Wu Y; He Q
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34590156
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
[TBL] [Abstract][Full Text] [Related]
14. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
Falasca M; Chiozzotto D; Godage HY; Mazzoletti M; Riley AM; Previdi S; Potter BV; Broggini M; Maffucci T
Br J Cancer; 2010 Jan; 102(1):104-14. PubMed ID: 20051961
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and structure-activity relationship of novel dichloroacetophenones targeting pyruvate dehydrogenase kinases with potent anticancer activity.
Xu B; Wang ZP; Liu Q; Yang X; Li X; Huang D; Qiu Y; Tam KY; Zhang SL; He Y
Eur J Med Chem; 2021 Mar; 214():113225. PubMed ID: 33550182
[TBL] [Abstract][Full Text] [Related]
16. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
17. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
19. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
Feldman RI; Wu JM; Polokoff MA; Kochanny MJ; Dinter H; Zhu D; Biroc SL; Alicke B; Bryant J; Yuan S; Buckman BO; Lentz D; Ferrer M; Whitlow M; Adler M; Finster S; Chang Z; Arnaiz DO
J Biol Chem; 2005 May; 280(20):19867-74. PubMed ID: 15772071
[TBL] [Abstract][Full Text] [Related]
20. Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway.
Saidel MÉ; Dos Santos KC; Nagano LFP; Montanari CA; Leitão A
Bioorg Med Chem Lett; 2017 Sep; 27(17):4001-4006. PubMed ID: 28774426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
